I am pleased to welcome your inquiry into our residency training program in the Department of Radiation Oncology here at Thomas Jefferson University. Our department offers a four-year, fully accredited residency and plans to review candidates for two positions, to begin in July 2025. Our program is accredited for eleven total residents.

We have been a leader in the area of organ preservation in breast, laryngeal, and colorectal cancer and have always been at the forefront of evaluating new technology. Over the past decade, our group has also gained increasing prominence in developing innovative approaches to brain tumors, prostate cancer, lung cancer, and clinical trial design. We have introduced new treatment planning and delivery tools into our clinic in recent years, including a dedicated stereotactic linear accelerator, intensity-modulated radiotherapy to extracranial sites, dedicated intraoperative radiotherapy site, and several innovative 3-D treatment planning systems. More than 2,000 new patients are seen at our five other treatment sites. We were one of the first institutions to treat patients with state-of-the-art ViewRay MRIdian technology, and we launched one of the country's first PLUVICTO (177Lu-PSMA-617) programs for treatment of metastatic prostate cancer. 

The oncology program throughout Jefferson, as organized within the NCI-designated Sidney Kimmel Comprehensive Cancer Center, has gained wide national recognition. Our department has a number of important leadership positions within NRG Oncology (we were former leaders in the Radiation Therapy Oncology Group). We are among the leading accruers to radiation oncology-oriented clinical trials in the nation. As a matter of fact, the RTOG was conceived by our founding chairman, Dr. Simon Kramer. All of our faculty are dedicated to postgraduate education and teach within the context of a multidisciplinary approach to cancer patients and cancer research. Our residents participate in a research rotation during their third year of training, and under the guidance of their Research Mentor, have published their work and presented at national conferences on a consistent basis. Our residents have also been the recipients of Radiological Society of North American (RSNA), Department of Defense (DoD), and Prostate Cancer Foundation (PCF) grants.

We look forward to reviewing your completed application and meeting you in the coming months.

Sincerely,

Adam P. Dicker, MD, PhD, FASTRO, FASCO
Enterprise Senior Vice President, Chair and Professor, Department of Radiation Oncology
Professor, Department of Pharmacology, Physiology, & Cancer Biology
Director, Jefferson Center for Digital Health & Data Science